Associate professor in Pharmacology (2009) at the Division of Clinical pharmacology, Department of laboratory Medicine, Karolinska Institutet
Doctorate of Philosophy (PhD) degree in Molecular genetics (2003) from Division molecular toxicology, Department of Environmental Medicine, Karolinska Institutet
Master of Science degree (MSc) in Biochemistry (1996) from Medical faculty, Addis Ababa University through Karolinska Institutet Research Training program (KIRT)
Bachelor degree in Pharmacy (B.Pharm, 1987) from School of Pharmacy, Addis Ababa University.
Project1: Optimization of TB-HIV co-treatment in Africa: pharmacogenetic and pharmacokinetic aspects of interaction between antiretroviral and anti-tuberculosis drugs. The optimal dose of efavirenz (an antiretroviral drug) to be given with rifampicin is not clear and the current recommendation by the different HIV-TB co-treatment guidelines is inconsistent. This project aims to identify the optimal dose of efavirenz to be given with rifampicin based anti-tuberculosis for TB-HIV co-infected patients: Efavirenz pharmacokinetics, pharmacogenetics, treatment efficacy (virologic and immunologic response) and safety (mortality, drug induced liver toxicity, immune reconstitution syndrome, neuropsychiatric toxicity etc) is monitored over one year period in HIV only versus TB-HIV co-infected patients This is a multinational research project financed by grants from European and developing counties clinical trial partnership (EDCTP) and SIDA
Project 2: Randomized clinical trial to identify optimal time to start antiretroviral treatment in TB-HIV co-infected patients receiving anti-tuberculosis therapy. Tuberculosis (TB) is the most common opportunistic infection and cause of death in HIV infected patients. TB/HIV co-treatment is recommended. However the timing of antiretroviral initiation after starting TB therapy remains controversial. Dispute centered upon whether early start of anti-retroviral therapy increases the risk of paradoxical reactions and adverse events or whether delay elevates the risk of disease progression and death. Aim of the study is to determine the most appropriate time to initiate anti-retroviral therapy in HIV/TB co-infected patients who recently started treatment for TB by comparing three treatment strategies of HAART initiation during anti-TB therapy.
Project 3: Discovery and validation of novel biomarkers for drug induced liver injury in human: Drug-induced liver injury (DILI) is the leading cause of acute liver failure and a major obstacle of drug development. The standard DILI biomarkers aminotransferase (ALT) and aspartate aminotransferase (AST) lack specificity and sensitivity whereas elevated bilirubin level indicates advanced liver injury. The study aims to discover and validate novel biomarkers for DILI for early signal of DILI from a well characterized patient cohort with the possibility to follow the time-course of the event using state-of-the-art biomarker discovery technology, genome-wide association-study, Proteomics and metbaolmoic approach. The study is financed by my research grant received from AstraZeneca.
Project 4: Healthcare associated infections, antimicrobial use and resistance: an intervention study for rational antimicrobials use, prevention of infection outbreak and to limit their spread to the community. Health care associated infection (HCAI) is a major global health problem causing increased hospital stay, cost of therapy and mortality. HCAIs are characterized by high rates of antimicrobial resistance and antibiotic use compared with those from community-acquired infections. Several studies indicated antimicrobial resistance and HCAIs is a major global problem particularly in Africa. This project focuses in two major areas that are inseparable (HCAIs + antimicrobial use and resistance). A three-phase prospective interventional study is being conducted at the largest referral university teaching Hospital in Addis Ababa. The project is financed by research grant obtained from Swedish research council and the Swedish civil contingency agency.
Academic honours, awards and prizes
Fellow of the Royal Collage of Physicians of Edinburgh: FRCP (Edin) http://www.rcpe.ac.uk/membership/fellowship
Vice chair and member of the Strategic Advisory Committee for European and Developing Countries Clinical Trial partnership (EDCTP) http://www.edctp.org/get-know-us/scientific-advisory-committee/
Honorary Professor of clinical Pharmacology at Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Serbia.